Can Bristol-Myers Squibb Recover?
The beaten-down shares of this high-quality pharmaceutical company should rebound with the economy.
Bristol-Myers Squibb doesn't have a pill to make shareholders feel better for the 30%-plus hit their stock has taken since peaking at $32 last July -- or, for that matter, for the 71% plunge since early 2001.
If you need a little pick-me-up for your portfolio, though, consider buying Bristol shares today. The stock (symbol BMY) is washed-out, suggesting little downside risk from current levels and, if a few things go right, the shares could gain 25% over the coming year.
But first, why the big drop? Bristol-Myers is in good company, having slid along with most of the other drug makers that are collectively known as big pharma. The two big concerns: Many major patents are due to expire in coming years, and a tighter regulatory environment will create a "revolutionary change" in the industry, says Credit Suisse analyst Catherine Arnold.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
She says the Food and Drug Administration will ratchet up scrutiny in the coming months, and the election of a Democratic president would put pressure on drug prices. Plans of both Hillary Clinton and Barak Obama include allowing Medicare to negotiate drug prices, which would effectively regulate pill prices, and permitting drugs that carry lower price tags in foreign countries to be re-imported to the U.S.
But Bristol is really cheap, much cheaper than I think this high-quality, profitable company deserves to be. At its March 28 close of $21.48, the stock is near both a 52-week and a five-year low.
Another pillar that should prop up the stock is its lush yield. Based on the annual cash dividend of $1.24 per share, which I think is secure, the stock yields 5.8%.
As for profits, analysts expect Bristol to earn $1.69 a share in 2008. That's a 14% increase over last year's earnings and compares with a 10% average earnings increase for the drug industry sector. Earnings "growth at rates near the top of big-pharma and a very attractive valuation" -- 13 times estimated '08 profits -- recently prompted Zacks Equity Research to bump up its rating on Bristol from hold to buy.
Earnings growth a few years down the line is a little shaky, though. The Zacks analysts, Brian Marckx and Jason Napodao say current earnings are driven by the "mega-blockbuster" drug Plavix, which helps prevent heart attack and stroke. However, they point out, the Plavix patent expires in 2011. Unlike some other drug companies, though, Bristol's pipeline contains some promising new drugs, which could fill the gap once Plavix generics start flooding the market.
But there's a big kicker. Given Bristol's low price, the Zacks analysts think the company is an attractive takeover candidate for even bigger drug companies, such as Sanofi or Pfizer.
Maybe. But if that doesn't happen, you can comfort yourself by collecting those fat dividends and watching the stock rise when the market rebounds.
-
S&P 500 Tops 7,000, Fed Pauses Rate Cuts: Stock Market TodayInvestors, traders and speculators will probably have to wait until after Jerome Powell steps down for the next Fed rate cut.
-
The Met Opera May Sell Its Iconic Paintings. Is it a Good Investment?Buying the Marc Chagall murals would come with a big stipulation attached.
-
Do You Really Need All Those Phone Plan Perks?Unlimited data plans now come bundled with streaming, travel perks and device deals — but many people pay for extras they rarely use.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
